137 related articles for article (PubMed ID: 31509041)
1. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia.
Yiau SK; Lee C; Mohd Tohit ER; Chang KM; Abdullah M
J Recept Signal Transduct Res; 2019 Jun; 39(3):276-282. PubMed ID: 31509041
[TBL] [Abstract][Full Text] [Related]
2. Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
Maha A; Cheong SK; Leong CF; Seow HF
Malays J Pathol; 2009 Dec; 31(2):81-91. PubMed ID: 20514850
[TBL] [Abstract][Full Text] [Related]
3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
4. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
5. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Andreeff M; Jiang S; Zhang X; Konopleva M; Estrov Z; Snell VE; Xie Z; Okcu MF; Sanchez-Williams G; Dong J; Estey EH; Champlin RC; Kornblau SM; Reed JC; Zhao S
Leukemia; 1999 Nov; 13(11):1881-92. PubMed ID: 10557066
[TBL] [Abstract][Full Text] [Related]
6. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
7. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
8. ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia.
Hayun M; Zaatra M; Itzkovich C; Sahar D; Rosenberg D; Filatova M; Ringelstein-Harlev S; Baris H; Moustafa-Hawash N; Louria-Hayon I; Ofran Y
Sci Rep; 2020 May; 10(1):8349. PubMed ID: 32433559
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
10. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
11. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
12. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
13. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
[TBL] [Abstract][Full Text] [Related]
14. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
15. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
van der Weide K; de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
Clin Cancer Res; 2009 May; 15(9):3076-83. PubMed ID: 19383813
[TBL] [Abstract][Full Text] [Related]
16. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
[TBL] [Abstract][Full Text] [Related]
17. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts.
Lunghi P; Tabilio A; Pinelli S; Valmadre G; Ridolo E; Albertini R; Carlo-Stella C; Dall'Aglio PP; Pelicci PG; Bonati A
Hematol J; 2001; 2(2):70-80. PubMed ID: 11423998
[TBL] [Abstract][Full Text] [Related]
18. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
19. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
20. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells.
Tokura Y; Shikami M; Miwa H; Watarai M; Sugamura K; Wakabayashi M; Satoh A; Imamura A; Mihara H; Katoh Y; Kita K; Nitta M
Leuk Res; 2002 Jan; 26(1):29-36. PubMed ID: 11734301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]